Sionna Therapeutics, Inc. (SION)
| Market Cap | 488.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.69M |
| Shares Out | 44.12M |
| EPS (ttm) | -15.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 186,207 |
| Open | 9.57 |
| Previous Close | 10.00 |
| Day's Range | 9.57 - 11.51 |
| 52-Week Range | 7.26 - 25.19 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 32.00 (+182.94%) |
| Earnings Date | May 25, 2025 |
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1... [Read more]
Analyst Forecast
According to one analyst, the rating for SION stock is "Strong Buy" and the 12-month stock price forecast is $32.0.
News
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline d...
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic f...
Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic f...
U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week
Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial ...
Sionna Therapeutics Prices Upsized Initial Public Offering
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fi...
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...
Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments
Sionna Therapeutics aims to raise $100 million in an IPO to advance its cystic fibrosis drug candidates, currently in Phase 1 and Phase 2 trials. The firm is well-capitalized with $137.5 million in ca...
Cystic fibrosis biotech Sionna Therapeutics files for a $100 million IPO
Sionna Therapeutics, a Phase 2 biotech developing novel therapies for cystic fibrosis, filed on Friday with the SEC to raise up to an estimated $100 million in an initial public offering.
Sionna Therapeutics IPO Registration Document (S-1)
Sionna Therapeutics has filed to go public with an IPO on the NASDAQ.